Tzang Bor-Show, Tsai Chun-Chou, Chiu Chun-Ching, Shi Jing-Yu, Hsu Tsai-Ching
Institute of Biochemistry and Biotechnology, Chung Shan Medical University, Taichung, Taiwan, Republic of China.
Clin Chim Acta. 2008 Sep;395(1-2):77-83. doi: 10.1016/j.cca.2008.05.012. Epub 2008 May 19.
Human parvovirus B19 infection has been frequently described as a cause or trigger of various autoimmune diseases. In previous studies, we have postulated the association among human parvovirus B19 (B19)-VP1 unique region (VP1u), production of anti-beta2-glycoprotein I (anti-beta2GPI) antibody and anti-phospholipid syndrome (APS)-like autoimmunity. However, the precise role of B19-VP1u in induction of APS is still obscure.
To further elucidate the pathogenic roles of VP1u in B19 infection and autoimmunity, we examined the effect of anti-B19-VP1u IgG antibodies on endothelial cells that is recognized to play crucial roles in APS. Human vascular endothelial cells, ECV-304, were incubated with various preparations of purified human or rabbit IgG. The activation of endothelial cells and production of cytokines were assessed by flow cytometry and ELISA, respectively.
Purified IgG from rabbits immunized with recombinant B19-VP1u proteins can up-regulate ICAM-1 (CD54), VCAM-1 (CD106), E-selectin (CD62E), MHC class II (HLA-DR, DP, DQ) molecule expression, and TNF-alpha production in endothelial cells as compared to those endothelial cells cultured with control IgG. Additionally, significantly increased phosphorylated-P38 mitogen-activated protein kinase (P38 MAPK) and iNOS were observed in both human anti-beta2GPI IgG and rabbit anti-B19-VP1u IgG treated-ECV-304 cells, respectively.
These experimental results imply that antibodies against B19-VP1u play important roles in the immunopathological processes as well as human anti-beta2GPI IgG that leads to development of APS by involving p38 phosphorylation and iNOS activation. It could provide a clue in understanding the role of anti-B19-VP1u antibodies in APS manifestations.
人类细小病毒B19感染常被描述为各种自身免疫性疾病的病因或触发因素。在先前的研究中,我们推测了人类细小病毒B19(B19)-VP1独特区域(VP1u)、抗β2-糖蛋白I(抗β2GPI)抗体的产生与抗磷脂综合征(APS)样自身免疫之间的关联。然而,B19-VP1u在APS诱导中的精确作用仍不清楚。
为了进一步阐明VP1u在B19感染和自身免疫中的致病作用,我们检测了抗B19-VP1u IgG抗体对内皮细胞的影响,已知内皮细胞在APS中起关键作用。将人血管内皮细胞ECV-304与各种纯化的人或兔IgG制剂一起孵育。分别通过流式细胞术和ELISA评估内皮细胞的活化和细胞因子的产生。
与用对照IgG培养的内皮细胞相比,用重组B19-VP1u蛋白免疫的兔纯化IgG可上调内皮细胞中ICAM-1(CD54)、VCAM-1(CD106)、E-选择素(CD62E)、MHC II类(HLA-DR、DP、DQ)分子的表达以及TNF-α的产生。此外,在人抗β2GPI IgG和兔抗B19-VP1u IgG处理的ECV-304细胞中分别观察到磷酸化-P38丝裂原活化蛋白激酶(P38 MAPK)和iNOS显著增加。
这些实验结果表明,抗B19-VP1u抗体在免疫病理过程中以及在导致APS发生的人抗β2GPI IgG中发挥重要作用,其通过涉及p38磷酸化和iNOS活化来实现。这可能为理解抗B19-VP1u抗体在APS表现中的作用提供线索。